To test new drugs and treatments for ALS/MND, researchers and pharmaceutical companies must perform clinical trials. A clinical trial is a therapeutic or observational research study to test whether a new drug or therapy is safe and effective for use in humans. Prior to any clinical trial, a drug must pass through a series of steps. See our Drug Pathways page to learn more about the approval phases of drugs or therapies.
For ALS/MND, there are many potential drugs and therapies currently undergoing clinical trials. Clinical trials are essential to new drug approvals. However, enrollment in a clinical trial should always be voluntary. People living with ALS/MND must consent prior to enrollment and have the right to know all pertinent details surrounding the trial.
The International Alliance of ALS/MND Associations provides information on drugs and therapies currently being researched. In addition, the resources below, contain a large database of known clinical trials for ALS/MND. These resources may be used to stay up to date on clinical trials for ALS/MND, as well as for people living with ALS/MND who are interested in enrolling in a clinical trial.
The following are resources on the topic of Drugs in Clinical Trial.
ALS Clinical Trials (ALS TDI)
People like you diagnosed with ALS play the most important role in the discovery and development of effective treatments and cures. Your participation in a clinical trial provides researchers with the data they need to determine whether or not a potential treatment ought to move closer to being available to all those with ALS. The ALS Therapy Development Institute is unbiased in listing clinical trials, providing information on all those enrolling worldwide. We encourage you to browse trials below and to subscribe to the clinical trial mailing list which will email you once a month with an update on changes to trials listed in this database.
Our mission is to translate scientific advances into new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND) as rapidly as possible.
To achieve our goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for ALS community.
NEALS was founded in 1995 with 9 academic clinical centers in the New England area. With help from The ALS Association’s TREAT ALS Network, Muscular Dystrophy Association, and our generous donors, the NEALS membership has grown to over 100 research centers committed to performing research in ALS and MND.